Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3572)
All Articles published online
|
Dec 27, 2012 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012; 4(12): 327-331 [PMID: 23355909 DOI: 10.4254/wjh.v4.i12.327] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v4/i12/327.htm |
| Number | Citing Articles |
| 1 |
Sadashiva S. Karnik, Hamiyet Unal, Jacqueline R. Kemp, Kalyan C. Tirupula, Satoru Eguchi, Patrick M. L. Vanderheyden, Walter G. Thomas, Eliot H. Ohlstein. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews 2015; 67(4): 754 doi: 10.1124/pr.114.010454
|
| 2 |
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica e Investigación en Arteriosclerosis (English Edition) 2017; 29(4): 185 doi: 10.1016/j.artere.2017.07.001
|
| 3 |
Yun‐Cheng Hsieh, Pei‐Shan Wu, Yi‐Tsung Lin, Yi‐Hsiang Huang, Ming‐Chih Hou, Kuei‐Chuan Lee, Han‐Chieh Lin. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. The FASEB Journal 2022; 36(10) doi: 10.1096/fj.202200594R
|
| 4 |
Hala Attia, Norah Albekairi, Layal Albdeirat, Arwa Soliman, Reem Rajab, Hend Alotaibi, Rehab Ali, Amira Badr, Jolanta Czuczejko. Chrysin Attenuates Fructose-Induced Nonalcoholic Fatty Liver in Rats via Antioxidant and Anti-Inflammatory Effects: The Role of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis. Oxidative Medicine and Cellular Longevity 2022; 2022: 1 doi: 10.1155/2022/9479456
|
| 5 |
Rosa Lombardi, Simona Onali, Douglas Thorburn, Brian R Davidson, Kurinchi Selvan Gurusamy, Emmanuel Tsochatzis. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD). Cochrane Database of Systematic Reviews 2017; 2017(4) doi: 10.1002/14651858.CD011640.pub2
|
| 6 |
Shiting Zhou, Jing Liu, Zhuo Li, Mingfeng Yang, Ruohe Sha, Ruike Yan, Xinxin Wang, Yanli Cao. The effect of different treatment strategies on glycolipid metabolism disorders and cardiovascular events in primary aldosteronism. Hypertension Research 2024; 47(6): 1719 doi: 10.1038/s41440-024-01648-0
|
| 7 |
Kurinchi Selvan Gurusamy, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy. Cochrane Database of Systematic Reviews. 2015; doi: 10.1002/14651858.CD011640
|
| 8 |
Ahad Eshraghian, Alireza Taghavi, Hamed Nikoupour, Saman Nikeghbalian, Seyed Ali Malek-Hosseini. Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02781-9
|
| 9 |
Aditi Kumar, Chad Blackshear, Jose S. Subauste, Nazanene H. Esfandiari, Elif Arioglu Oral, Angela R. Subauste. Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study. Journal of the Endocrine Society 2017; 1(5): 460 doi: 10.1210/js.2017-00055
|
| 10 |
Edwyn O. Cruz-López, Dien Ye, Congqing Wu, Hong S. Lu, Estrellita Uijl, Katrina M. Mirabito Colafella, A.H. Jan Danser. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. Hypertension 2022; 79(10): 2115 doi: 10.1161/HYPERTENSIONAHA.122.18731
|
| 11 |
Aswathy R. Devan, Bhagyalakshmi Nair, Ayana R. Kumar, Lekshmi R. Nath. An insight into the role of telmisartan as PPAR‐γ/α dual activator in the management of nonalcoholic fatty liver disease. Biotechnology and Applied Biochemistry 2022; 69(2): 461 doi: 10.1002/bab.2123
|
| 12 |
Ji Hye Huh, Jang Young Kim, Eunhee Choi, Jae Seok Kim, Yoosoo Chang, Ki-Chul Sung, Tatsuo Shimosawa. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLOS ONE 2017; 12(7): e0180951 doi: 10.1371/journal.pone.0180951
|
| 13 |
Kuei-Chuan Lee, Che-Chang Chan, Ying-Ying Yang, Yun-Cheng Hsieh, Yi-Hsiang Huang, Han-Chieh Lin, Rafael Aldabe. Aliskiren Attenuates Steatohepatitis and Increases Turnover of Hepatic Fat in Mice Fed with a Methionine and Choline Deficient Diet. PLoS ONE 2013; 8(10): e77817 doi: 10.1371/journal.pone.0077817
|
| 14 |
Christian Zanza, Michele Fidel Tassi, Tatsiana Romenskaya, Fabio Piccolella, Ludovico Abenavoli, Francesco Franceschi, Andrea Piccioni, Veronica Ojetti, Angela Saviano, Barbara Canonico, Mariele Montanari, Loris Zamai, Marco Artico, Chiara Robba, Fabrizio Racca, Yaroslava Longhitano. Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019. Cells 2021; 10(7): 1752 doi: 10.3390/cells10071752
|
| 15 |
Oluyemi Komolafe, Elena Buzzetti, Audrey Linden, Lawrence MJ Best, Angela M Madden, Danielle Roberts, Thomas JG Chase, Dominic Fritche, Suzanne C Freeman, Nicola J Cooper, Alex J Sutton, Elisabeth Jane Milne, Kathy Wright, Chavdar S Pavlov, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2021; 2021(7) doi: 10.1002/14651858.CD013157.pub2
|
| 16 |
Cheng Han Ng, Zhen Yu Wong, Nicholas W. S. Chew, Kai En Chan, Jieling Xiao, Nilofer Sayed, Wen Hui Lim, Darren Jun Hao Tan, Ryan Wai Keong Loke, Phoebe Wen Lin Tay, Jie Ning Yong, Gywneth Kong, Daniel Q. Huang, Jiong-Wei Wang, Mark Chan, Mayank Dalakoti, Nobuharu Tamaki, Mazen Noureddin, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Frontiers in Cardiovascular Medicine 2022; 9 doi: 10.3389/fcvm.2022.942753
|
| 17 |
Federico Carbone, Fabrizio Montecucco, François Mach, Roberto Pontremoli, Francesca Viazzi. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thrombosis and Haemostasis 2013; 110(11): 940 doi: 10.1160/TH13-06-0499
|
| 18 |
Floriana Elvira Ionică, Simona Negreș, Ludovic Bejenaru, Cornelia Bejenaru, Cornel Chiriță. Pharmacological Approaches for Nonalcoholic Fatty Liver Disease. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 2016; 23(3) doi: 10.1515/rjdnmd-2016-0037
|
| 19 |
J K Dyson, Q M Anstee, S McPherson. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterology 2014; 5(4): 277 doi: 10.1136/flgastro-2013-100404
|
| 20 |
Ekrem Aksu, Abdullah Sokmen, Murat Ispiroglu, Kadir Gisi, Enes Celik, Ahmet Cagri Aykan. Early cardiac electrical and structural changes in patients with non-obese non-alcoholic fatty liver disease. Kardiologiia 2021; 61(5): 51 doi: 10.18087/cardio.2021.5.n1416
|
| 21 |
Nishika Sahini, Jürgen Borlak. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Progress in Lipid Research 2014; 54: 86 doi: 10.1016/j.plipres.2014.02.002
|
| 22 |
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath. ACE2: from protection of liver disease to propagation of COVID-19. Clinical Science 2020; 134(23): 3137 doi: 10.1042/CS20201268
|
| 23 |
Maria Ryaboshapkina, Mårten Hammar. Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10930-w
|
| 24 |
Kuei-Chuan Lee, Yun-Cheng Hsieh, Ying-Ying Yang, Che-Chang Chan, Yi-Hsiang Huang, Han-Chieh Lin. Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice. Scientific Reports 2016; 6(1) doi: 10.1038/srep18899
|
| 25 |
Gjin Ndrepepa, Roisin Colleran, Adnan Kastrati. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clinica Chimica Acta 2018; 476: 130 doi: 10.1016/j.cca.2017.11.026
|
| 26 |
Antonella Amato, Gaetano-Felice Caldara, Domenico Nuzzo, Sara Baldassano, Pasquale Picone, Manfredi Rizzo, Flavia Mulè, Marta Di Carlo. NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. Nutrients 2017; 9(5): 492 doi: 10.3390/nu9050492
|
| 27 |
Jillian Price, Carey Escheik, Ali Weinstein, Patrice Winter, Lynn Gerber, Zobair Younossi. Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease. The Journal of Clinical Hypertension 2020; 22(10): 1915 doi: 10.1111/jch.13938
|
| 28 |
Yoonmi Park, Stephanie A. Smith-Warner, Xuehong Zhang, Yoon Jung Park, Hyesook Kim, Hyesook Park, Hye Ah Lee, Seungyoun Jung. Association between use of vitamin and mineral supplement and non-alcoholic fatty liver disease in hypertensive adults. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-40868-1
|
| 29 |
Ji Hye Huh, Song Vogue Ahn, Sang Baek Koh, Eunhee Choi, Jang Young Kim, Ki-Chul Sung, Eung Ju Kim, Jeong Bae Park, Vincent Wong. A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. PLOS ONE 2015; 10(11): e0143560 doi: 10.1371/journal.pone.0143560
|
| 30 |
Edyta Maslak, Piotr Zabielski, Kamila Kochan, Kamil Kus, Agnieszka Jasztal, Barbara Sitek, Bartosz Proniewski, Tomasz Wojcik, Katarzyna Gula, Agnieszka Kij, Maria Walczak, Małgorzata Baranska, Adrian Chabowski, Ryan J. Holland, Joseph E. Saavedra, Larry K. Keefer, Stefan Chlopicki. The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. Biochemical Pharmacology 2015; 93(3): 389 doi: 10.1016/j.bcp.2014.12.004
|
| 31 |
Ali Mahmoudi, Mehdi Rostami, Mohammad Mahdi Hajihasani, Vasily N. Sukhorukov, Prashant Kesharwani, Amirhossein Sahebkar. siRNA-mediated gene silencing for non-alcoholic fatty liver disease: A comprehensive review of molecular targets. European Polymer Journal 2024; 208: 112866 doi: 10.1016/j.eurpolymj.2024.112866
|
| 32 |
Apostolis PAPAEFTHYMIOU, Michael DOULBERIS, Kyriaki KARAFYLLIDOU, Eleftherios CHATZIMICHAEL, Georgia DERETZI, Aristomenis K. EXADAKTYLOS, Fotios SAMPSONAS, Athanasios GELASAKIS, Spyros I. PAPAMICHOS, Georgios KOTRONIS, Dimitra GIALAMPRINOU, Elisabeth VARDAKA, Stergios A. POLYZOS, Jannis KOUNTOURAS. Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. Minerva Endocrinology 2023; 48(3) doi: 10.23736/S2724-6507.21.03564-8
|
| 33 |
Manas Kumar Panigrahi, Prajna Anirvan. Letter to the editor: Using angiotensin‐converting enzyme inhibitors to prevent liver‐related events in NAFLD—Revisiting the renin–angiotensin–aldosterone system pathways. Hepatology 2022; 76(2): E32 doi: 10.1002/hep.32432
|
| 34 |
Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair D. Burt, Elaine McColl, Deborah D. Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury, Derek Mann, Quentin M. Anstee, Christopher P. Day, Vincent Wong. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLOS ONE 2017; 12(4): e0175717 doi: 10.1371/journal.pone.0175717
|
| 35 |
Konstantinos Tziomalos. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World Journal of Hepatology 2014; 6(10): 738-744 doi: 10.4254/wjh.v6.i10.738
|
| 36 |
Abdulrahman Ismaiel, Dan L. Dumitrascu. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. American Journal of Therapeutics 2023; 30(3): e242 doi: 10.1097/MJT.0000000000001174
|
| 37 |
J K Dyson, Q M Anstee, S McPherson. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgraduate Medical Journal 2015; 91(1072): 92 doi: 10.1136/postgradmedj-2013-100404rep
|
| 38 |
George B Goh, Mangesh R Pagadala, Jaividhya Dasarathy, Aynur Unalp‐Arida, Ruth Sargent, Carol Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa Yerian, Rish Pai, Arthur J McCullough, Srinivasan Dasarathy. Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease. Liver International 2015; 35(3): 979 doi: 10.1111/liv.12611
|
| 39 |
Kurinchi Selvan Gurusamy, Emmanuel Tsochatzis, Angela M Madden. Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2018; doi: 10.1002/14651858.CD013157
|
| 40 |
Jiao Xin, Tingyu You, Xiangfu Jiang, Dongdong Fu, Jiarong Wang, Wei Jiang, Xiaowen Feng, Jiagen Wen, Yan Huang, Chengmu Hu. Caveolin-1 Alleviates Acetaminophen—Induced Hepatotoxicity in Alcoholic Fatty Liver Disease by Regulating the Ang II/EGFR/ERK Axis. International Journal of Molecular Sciences 2022; 23(14): 7587 doi: 10.3390/ijms23147587
|
| 41 |
Amira M. Badr, Iman O. Sherif, Yasmen F. Mahran, Hala A. Attia. The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases. Advances in Biochemistry in Health and Disease 2023; 25: 179 doi: 10.1007/978-3-031-23621-1_10
|
| 42 |
Lidija Orlic, Ivana Mikolasevic, Vesna Lukenda, Kata Anic, Ita Jelic, Sanjin Racki. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wiener klinische Wochenschrift 2015; 127(9-10): 355 doi: 10.1007/s00508-014-0661-y
|
| 43 |
Xinrong Zhang, Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Lilian Yan Liang, Vicki Wing‐Ki Hui, Huapeng Lin, Guan‐Lin Li, Jimmy Che‐To Lai, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong. Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease. Hepatology 2022; 76(2): 469 doi: 10.1002/hep.32294
|
| 44 |
Elena Buzzetti, Audrey Linden, Lawrence MJ Best, Angela M Madden, Danielle Roberts, Thomas J G Chase, Suzanne C Freeman, Nicola J Cooper, Alex J Sutton, Dominic Fritche, Elisabeth Jane Milne, Kathy Wright, Chavdar S Pavlov, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2021; 2021(6) doi: 10.1002/14651858.CD013156.pub2
|
| 45 |
Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi. Pharmacological management of nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1183 doi: 10.1016/j.metabol.2016.04.004
|
| 46 |
Olcay Ozveren, Cemil Izgi, Elif Eroglu, Mustafa Aytek Simsek, Ayca Turer, Zekeriya Kucukdurmaz, Veysel Cinar, Muzaffer Degertekin. Doppler Tissue Evaluation of Atrial Conduction Properties in Patients With Non-alcoholic Fatty-liver Disease. Ultrasonic Imaging 2016; 38(3): 225 doi: 10.1177/0161734615595015
|
| 47 |
Rafael Antonio Vargas Vargas, Jesús María Varela Millán, Esperanza Fajardo Bonilla. Renin–angiotensin system: Basic and clinical aspects—A general perspective. Endocrinología, Diabetes y Nutrición 2022; 69(1): 52 doi: 10.1016/j.endinu.2021.05.012
|
| 48 |
Kurinchi Selvan Gurusamy, Emmanuel Tsochatzis, Angela M Madden. Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2018; doi: 10.1002/14651858.CD013156
|
| 49 |
Natalia Muñoz-Durango, Marco Arrese, Alejandra Hernández, Evelyn Jara, Alexis M. Kalergis, Daniel Cabrera. A Mineralocorticoid Receptor Deficiency in Myeloid Cells Reduces Liver Steatosis by Impairing Activation of CD8+ T Cells in a Nonalcoholic Steatohepatitis Mouse Model. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.563434
|
| 50 |
Jose Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chaponan-Lavalle, Karla Hernandez Randich, Diego Chambergo-Michilot, Herson Flores Sanga, Pornthira Mutirangura. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World Journal of Cardiology 2023; 15(7): 328-341 doi: 10.4330/wjc.v15.i7.328
Abstract(604) |
Core Tip(392) |
Full Article(HTML)(2402)
|
Full Article with Cover (PDF)-1468K(95)
|
Full Article (Word)-335K(88)
|
Audio-441K(1)
|
Peer-Review Report-231K(52)
|
Answering Reviewers-167K(47)
|
Full Article (PDF)-1214K(414)
|
Full Article (XML)-257K(59)
|
Times Cited (2)
|
Total Visits (6000)
|
Open
|
| 51 |
Li‐hui Yan, Biao Mu, Yue Guan, Xinyu Liu, Nan Zhao, Da Pan, Shao‐zhen Wang. Assessment of the relationship between non‐alcoholic fatty liver disease and diabetic complications. Journal of Diabetes Investigation 2016; 7(6): 889 doi: 10.1111/jdi.12518
|
| 52 |
Fuyuko Takahashi, Yoshitaka Hashimoto, Ayumi Kaji, Ryosuke Sakai, Yuka Kawate, Takuro Okamura, Noriyuki Kitagawa, Hiroshi Okada, Naoko Nakanishi, Saori Majima, Takafumi Osaka, Takafumi Senmaru, Emi Ushigome, Masahide Hamaguchi, Michiaki Fukui. The Association of Salt Intake and Non-alcoholic Fatty Liver Disease in People With Type 2 Diabetes: A Cross-Sectional Study. Frontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.943790
|
| 53 |
Renuka Munshi, Miteshkumar Maurya. The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases. Advances in Biochemistry in Health and Disease 2023; 25: 113 doi: 10.1007/978-3-031-23621-1_7
|
| 54 |
Chieko Ejima, Haruna Kuroda, Sonoko Ishizaki. A novel diet‐induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis. Physiological Reports 2016; 4(21) doi: 10.14814/phy2.13016
|
| 55 |
Rafael Antonio Vargas Vargas, Jesús María Varela Millán, Esperanza Fajardo Bonilla. Renin–angiotensin system: Basic and clinical aspects—A general perspective. Endocrinología, Diabetes y Nutrición (English ed.) 2022; 69(1): 52 doi: 10.1016/j.endien.2022.01.005
|
| 56 |
Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Tomohiro Otani, Takashi Kobayashi, Asako Nogami, Satoru Saito, Atsushi Nakajima. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis. Expert Opinion on Emerging Drugs 2024; 29(2): 127 doi: 10.1080/14728214.2024.2328036
|
| 57 |
Seema Patel, Abdur Rauf, Haroon Khan, Tareq Abu-Izneid. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomedicine & Pharmacotherapy 2017; 94: 317 doi: 10.1016/j.biopha.2017.07.091
|
| 58 |
Neel Malhotra, Melanie D Beaton. Management of non-alcoholic fatty liver disease in 2015. World Journal of Hepatology 2015; 7(30): 2962-2967 doi: 10.4254/wjh.v7.i30.2962
|
| 59 |
Yu Wu, Kun L. Ma, Yang Zhang, Yi Wen, Gui H. Wang, Ze B. Hu, Liang Liu, Jian Lu, Pei P. Chen, Xiong Z. Ruan, Bi C. Liu. Lipid disorder and intrahepatic renin–angiotensin system activation synergistically contribute to non‐alcoholic fatty liver disease. Liver International 2016; 36(10): 1525 doi: 10.1111/liv.13131
|
| 60 |
LORENA CASTRO S., GUILLERMO SILVA P.. HÍGADO GRASO NO ALCOHÓLICO. Revista Médica Clínica Las Condes 2015; 26(5): 600 doi: 10.1016/j.rmclc.2015.09.006
|
| 61 |
Antonella Mirizzi, Isabella Franco, Carla Maria Leone, Caterina Bonfiglio, Raffaele Cozzolongo, Maria Notarnicola, Vito Giannuzzi, Valeria Tutino, Valentina De Nunzio, Irene Bruno, Claudia Buongiorno, Angelo Campanella, Valentina Deflorio, Annamaria Pascale, Filippo Procino, Paolo Sorino, Alberto Rubén Osella. Effects of Some Food Components on Non-Alcoholic Fatty Liver Disease Severity: Results from a Cross-Sectional Study. Nutrients 2019; 11(11): 2744 doi: 10.3390/nu11112744
|
| 62 |
Amandeep Singh, Rajat Garg, Nan Lan, Mohamed Tausif Siddiqui, Mohit Gupta, Naim Alkhouri. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian Journal of Gastroenterology 2020; 39(6): 591 doi: 10.1007/s12664-020-01087-y
|
| 63 |
Meital Charni-Natan, Ronit Aloni-Grinstein, Etty Osher, Varda Rotter. Liver and Steroid Hormones—Can a Touch of p53 Make a Difference?. Frontiers in Endocrinology 2019; 10 doi: 10.3389/fendo.2019.00374
|
| 64 |
Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Virend Somers, Seung Up Kim, C. Anwar A. Chahal, Vincent Wai-Sun Wong, Jingjing Cai, Michael D. Shapiro, Mohammed Eslam, Philippe Gabriel Steg, Ki-Chul Sung, Anoop Misra, Jian-Jun Li, Carlos Brotons, Yuli Huang, George V. Papatheodoridis, Aijun Sun, Yusuf Yilmaz, Wah Kheong Chan, Hui Huang, Nahum Méndez-Sánchez, Saleh A. Alqahtani, Helena Cortez-Pinto, Gregory Y. H. Lip, Robert J. de Knegt, Ponsiano Ocama, Manuel Romero-Gomez, Marat Fudim, Giada Sebastiani, Jang Won Son, John D. Ryan, Ignatios Ikonomidis, Sombat Treeprasertsuk, Daniele Pastori, Monica Lupsor-Platon, Herbert Tilg, Hasmik Ghazinyan, Jerome Boursier, Masahide Hamaguchi, Mindie H. Nguyen, Jian-Gao Fan, George Boon-Bee Goh, Mamun Al Mahtab, Saeed Hamid, Nilanka Perera, Jacob George, Ming-Hua Zheng. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatology International 2023; 17(4): 773 doi: 10.1007/s12072-023-10543-8
|
| 65 |
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico. Clínica e Investigación en Arteriosclerosis 2017; 29(4): 185 doi: 10.1016/j.arteri.2016.06.002
|
| 66 |
Ilias D. Vachliotis, Stergios A. Polyzos. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current Obesity Reports 2023; 12(3): 191 doi: 10.1007/s13679-023-00519-y
|
| 67 |
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher, Paola Loria. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015; 9(5): 629 doi: 10.1586/17474124.2015.965143
|
| 68 |
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
|
| 69 |
Yue Li, Feng Xiong, Wen Xu, Side Liu. Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot Study. Gastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/5647161
|